Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Urol Case Rep ; 37: 101626, 2021 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-33816119

RESUMEN

Testicular prostheses are utilized to improve cosmetic outcomes and reduce the psychological impact of native tissue loss particularly related to trauma, neoplasm, or malignancy. Implant rupture is usually related to trauma and spontaneous prosthesis rupture is a rare event. We report a case of an incidental spontaneous rupture in an asymptomatic patient status post orchiectomy and silicone gel filled prosthesis insertion for left cryptorchidism. The role of imaging has become increasingly important for evaluating implant integrity. By recognizing the imaging characteristics associated with implant rupture, radiologists can aid in early complication detection prior to the onset of clinical symptoms.

2.
J Drugs Dermatol ; 16(8): 810-812, 2017 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-28809996

RESUMEN

Granular parakeratosis, originally named axillary granular parakeratosis, is an uncommon disease with an unclear etiology. It is thought to result from defective processing of profillagrin to fillagrin, causing retention of keratohyaline granules in the epidermis. A myriad of causative factors has been proposed, including friction, moisture, heat, and contact irritants such as deodorants. We present a case in the inframammary area that resolved with mastopexy, further supporting the role of friction, moisture, and heat. Furthermore, we present electron microscopic evidence demonstrating non-degraded keratohyaline granules upon epidermal maturation. This entity, we believe, is reactive and represents a protective response of the body to moisture and heat.

J Drugs Dermatol. 2017;16(8):810-812.

.


Asunto(s)
Axila , Paraqueratosis/diagnóstico , Adulto , Diagnóstico Diferencial , Femenino , Humanos , Paraqueratosis/cirugía
3.
J Neurosci ; 32(42): 14592-601, 2012 Oct 17.
Artículo en Inglés | MEDLINE | ID: mdl-23077045

RESUMEN

The chemokine CX3CL1/fractalkine is expressed by neurons as a transmembrane-anchored protein that can be cleaved to yield a soluble isoform. However, the roles for these two types of endogenous CX3CL1 in neurodegenerative pathophysiology remain elusive. As such, it has been difficult to delineate the function of the two isoforms of CX3CL1, as both are natively present in the brain. In this study we examined each isoform's ability to regulate neuroinflammation in a mouse model of Parkinson's disease initiated by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). We were able to delineate the function of both CX3CL1 isoforms by using adeno-associated virus-mediated gene therapy to selectively express synthetic variants of CX3CL1 that remain either permanently soluble or membrane bound. In the present study we injected each CX3CL1 variant or a GFP-expressing vector directly into the substantia nigra of CX3CL1(-/-) mice. Our results show that only the soluble isoform of CX3CL1 is sufficient for neuroprotection after exposure to MPTP. Specifically, we show that the soluble CX3CL1 isoform reduces impairment of motor coordination, decreases dopaminergic neuron loss, and ameliorates microglial activation and proinflammatory cytokine release resulting from MPTP exposure. Furthermore, we show that the membrane-bound isoform provides no neuroprotective capability to MPTP-induced pathologies, exhibiting similar motor coordination impairment, dopaminergic neuron loss, and inflammatory phenotypes as MPTP-treated CX3CL1(-/-) mice, which received the GFP-expressing control vector. Our results reveal that the neuroprotective capacity of CX3CL1 resides solely upon the soluble isoform in an MPTP-induced model of Parkinson's disease.


Asunto(s)
Quimiocina CX3CL1/fisiología , Modelos Animales de Enfermedad , Enfermedad de Parkinson/metabolismo , Enfermedad de Parkinson/prevención & control , 1-Metil-4-fenil-1,2,3,6-Tetrahidropiridina/administración & dosificación , Animales , Quimiocina CX3CL1/deficiencia , Quimiocina CX3CL1/uso terapéutico , Cuerpo Estriado/efectos de los fármacos , Cuerpo Estriado/metabolismo , Cuerpo Estriado/patología , Neuronas Dopaminérgicas/efectos de los fármacos , Neuronas Dopaminérgicas/metabolismo , Neuronas Dopaminérgicas/patología , Células HEK293 , Humanos , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Fármacos Neuroprotectores/uso terapéutico , Enfermedad de Parkinson/etiología , Isoformas de Proteínas/biosíntesis , Isoformas de Proteínas/deficiencia , Isoformas de Proteínas/uso terapéutico , Distribución Aleatoria , Solubilidad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...